Jestor vs Andson Biotech
Side-by-side comparison of AI visibility scores, market position, and capabilities
No-code platform for building custom internal tools, workflows, and databases without coding; YC-backed with $1.7M revenue competing with Airtable and Retool for business process automation.
About
Jestor is a no-code/low-code platform that enables businesses to build custom internal tools, automate workflows, and manage structured data without writing software — providing a visual interface to create database-backed applications for operations like inventory tracking, project management, client onboarding, and field team coordination. Founded in 2019 in San Francisco and a Y Combinator W21 graduate, Jestor raised $458,000 in funding and grew revenue to $1.7 million in 2024 with a 17-person team.\n\nJestor's platform allows operations and business users to create custom applications by defining data structures (like a database table editor), adding form interfaces for data input, and creating automations that trigger actions when records change — sending notifications, updating related records, integrating with external services. The target user is a business operator or product manager who can describe what they want ("a system where our field technicians can log service visits and managers can review and approve reports") and build it without engineering support.\n\nIn 2025, Jestor competes in the no-code internal tools and business process automation market with Airtable (the dominant no-code database platform), Notion (collaborative work management), Retool (internal tools for technical users), and AppSheet (Google's no-code app builder) for custom business application building. The no-code market has grown substantially as digital operations become the standard for businesses that lack dedicated software teams. Jestor's 2025 strategy focuses on deepening workflow automation capabilities, growing in Latin America (where the company has strong early traction and where no-code tools serve the large SMB market underserved by enterprise software), and building templates that accelerate specific industry use cases (logistics, field service, professional services).
Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.
About
Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.